查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1718043

生物医学市场人工智慧的组件、技术、业务功能、应用、最终用户和部署模式—2025-2030 年全球预测

Artificial Intelligence in Biomedical Market by Component, Technology, Business Function, Application, End User, Deployment Mode - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计生物医学人工智慧市场规模到 2024 年将达到 28.7 亿美元，到 2025 年将达到 32.6 亿美元，年复合成长率为 14.65%，到 2030 年将达到 65.3 亿美元。

主要市场统计数据
基准年2024年 28.7亿美元
预计2025年 32.6亿美元
预测年份 2030 65.3亿美元
复合年增长率（%） 14.65%

人工智慧的快速发展不仅仅是技术的进步；它代表了生物医学领域的模式转移。在过去的十年中，机器学习、数据分析和计算生物学的突破性进展重新定义了研究的进行方式、诊断的开展方式以及患者照护方式。这种转变由多学科专业知识和不断增长的生物医学数据的整合所推动，使人工智慧成为加速创新的重要工具。

在这个不断变化的情况下，专家和决策者不断面临挑战，需要确定将资源投入到哪里才能发挥最大作用。这是一个科技与医疗保健之间合作日益加强的故事，先进的演算法与传统的生物医学方法携手并进。因此，这些学科的融合不仅会提高业务效率，还会为个人化医疗和预测分析铺平道路。

以下部分全面概述了推动人工智慧与生物医学应用交叉、细分洞察、区域动态和公司策略的关键转变。每个部分都经过仔细研究，呈现出快速变化的行业的整体情况，在这个行业中，利用数位转型的力量正在推动临床实践和研究的突破。

改变潮流：重新定义生物医学人工智慧

近年来，生物医药产业经历了变革性的变化，重新定义了研究和治疗方法。先进演算法模型和计算能力的涌入使得诊断和药物开发的预测能够更快、更准确。这种转变是由技术平台和调查方法的深度融合所推动的，数位工具使曾经只需要人类专业知识就能完成的任务标准化。

这种转变的主要驱动力是机器学习技术的成熟，当与大型资料集结合时，机器学习技术大大减少了临床决策流程所需的时间。增强的数据视觉化和高级分析使相关人员能够识别以前无法察觉的细微趋势。这些发展将促进从被动医疗转向主动介入策略的转变，最终改善患者的治疗效果。

此外，云端处理、边缘设备和互联繫统的集成为生物医学创新的新时代奠定了基础，实现了安全的数据共用和更全面的病患监测方法。随着自然语言处理和机器人流程自动化等技术的成熟，它们提供了可扩展的解决方案，将常规业务转变为智慧、自我最佳化的生态系统。这项突破不仅仅是渐进式的改进，而是对生物医学研究方式和医疗保健方式的全面重新思考。

关键细分洞察 深入探究市场方面

细分洞察提供了一个广泛的框架，有助于理解生物医学人工智慧市场的不同方面。基于组件的分析强调硬体、服务和软体的划分，其中硬体进一步分解为记忆体、网路设备和处理器。对服务业的分析着重于咨询、实施、整合和维护，而对软体业的分析则涵盖应用程式、中介软体和平台。这些层次突显了技术整合和营运支援的多面性。

如果我们根据技术研究市场，该领域可细分为电脑视觉、机器学习、自然语言处理和机器人流程自动化。电脑视觉本身是透过脸部辨识脸辨识、影像识别和模式辨识等功能进行研究的。机器学习进一步分为深度学习、强化学习、监督学习和无监督学习，以确保捕捉到每个分析细微差别。除此之外，自然语言处理还涉及聊天机器人、语言翻译、语音辨识和文字分析，而机器人流程自动化则分为有人值守自动化和无人值守自动化。

基于业务功能的细分透过专注于客户服务、财务和营运来揭示复杂性。客户服务涉及客户回馈分析和个人化支持，财务专注于诈欺侦测和风险管理，营运包括流程最佳化和资源分配。临床试验着重于数据分析和招募、病理学和放射学诊断、远端监测方法和可穿戴设备的病患监测以及药物发现和精准医疗的治疗。

进一步基于最终用户的分析确定了学术和研究机构、政府机构、医疗保健提供者、製药公司等细分市场。这些细分市场进一步细分为研究中心和大学、公共卫生组织和监管机构、诊所和医院以及生物技术和医疗技术公司。云端基础的模型分为混合云端、私有云端和公共云端框架。综合起来，这些细分为相关人员提供了复杂的蓝图，以便更好地制定生物医学人工智慧市场的策略。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 对改进诊断工具和改善患者治疗结果的需求日益增加
      • 个人化医疗需求的不断增长将推动人工智慧在生物医学实践中的应用
      • 医疗保健数据激增
    • 限制因素
      • 目前人工智慧演算法在准确理解复杂生物系统方面的局限性
    • 机会
      • 应用自然语言处理来增强临床决策和数据分析
      • 利用人工智慧驱动的运算模型和模拟增强研发
    • 任务
      • 管理生物医学人工智慧应用中的数据偏差和准确性问题
  • 市场区隔分析
    • 技术：人工智慧技术对生物医学创新和商业策略的变革性影响
    • 应用：由于诊断准确性和速度的提高，人工智慧应用将在病理学和放射学领域蓬勃发展
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章 生物医药市场中的人工智慧（按组成部分）

  • 硬体
    • 记忆
    • 网路装置
    • 处理器
  • 服务
    • 咨询
    • 执行
    • 一体化
    • 维护
  • 软体
    • 应用
    • 中介软体
    • 平台

第七章 生物医药市场中的人工智慧（按技术）

  • 电脑视觉
    • 脸部辨识
    • 影像识别
    • 模式识别
  • 机器学习
    • 深度学习
    • 强化学习
    • 监督学习
    • 无监督学习
  • 自然语言处理
    • 聊天机器人
    • 语言翻译
    • 语音辨识
    • 文字分析
  • 机器人流程自动化
    • 有人值守自动化
    • 无人自动化

第八章生物医药市场中的人工智慧（业务功能）

  • 客户服务
    • 客户回馈分析
    • 个人化支援
  • 金融
    • 诈欺侦测
    • 风险管理
  • 手术
    • 流程优化
    • 资源分配

第九章 生物医药市场中的人工智慧应用

  • 临床试验
    • 数据分析
    • 招募
  • 诊断
    • 病理
    • 放射学
  • 病患监测
    • 远端监控
    • 穿戴式装置
  • 治疗
    • 药物研发
    • 精准医疗

第 10 章。生物医药市场中的人工智慧（按最终用户）

  • 学术研究所
    • 研究中心
    • 大学
  • 政府
    • 公共卫生机构
    • 监管机构
  • 医疗保健提供者
    • 诊所
    • 医院
  • 製药公司
    • 生技公司
    • 医疗技术公司

第 11 章。按部署模式分類的生物医药市场中的人工智慧

  • 云端基础
    • 混合云端
    • 私有云端
    • 公共云端
  • 本地

12. 美国生物医药人工智慧市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

13. 亚太地区生物医药人工智慧市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

14. 欧洲、中东和非洲生物医药市场人工智慧

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • AiCure, LLC
  • Arterys Inc.
  • Aspen Technology Inc
  • Atomwise Inc
  • Augmedix, Inc.
  • Behold.ai Technologies Limited
  • BenevolentAI SA
  • BioSymetrics Inc.
  • BPGbio Inc.
  • Butterfly Network, Inc.
  • Caption Health, Inc. by GE Healthcare
  • Cloud Pharmaceuticals, Inc.
  • CloudMedX Inc.
  • Corti ApS
  • Cyclica Inc by Recursion Pharmaceuticals, Inc.
  • Deargen Inc
  • Deep Genomics Incorporated
  • Euretos BV
  • Exscientia plc
  • Google, LLC by Alphabet, Inc.
  • Insilico Medicine
  • Intel Corporation
  • International Business Machines Corporation
  • InveniAI LLC
  • Isomorphic Labs
  • Novo Nordisk A/S
  • Sanofi SA
  • Turbine Ltd.
  • Viseven Europe OU
  • XtalPi Inc.
Product Code: MRR-A6768A62EDFF

The Artificial Intelligence in Biomedical Market was valued at USD 2.87 billion in 2024 and is projected to grow to USD 3.26 billion in 2025, with a CAGR of 14.65%, reaching USD 6.53 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 2.87 billion
Estimated Year [2025] USD 3.26 billion
Forecast Year [2030] USD 6.53 billion
CAGR (%) 14.65%

The rapid evolution of artificial intelligence is not merely a technological advancement; it represents a paradigm shift in the biomedical sphere. Over the past decade, breakthroughs in machine learning, data analytics, and computational biology have redefined how research is conducted, diagnostics are made, and patient care is delivered. This transformation is bolstered by an integration of multidisciplinary expertise and an ever-increasing volume of biomedical data, making AI an indispensable tool in accelerating innovation.

In this evolving landscape, professionals and decision-makers are consistently challenged with discerning where to invest resources for maximum impact. The narrative that emerges is one of increased collaboration between technology and healthcare, where advanced algorithms work hand in hand with traditional biomedical methods. As a result, the convergence of these realms is not only enhancing operational efficiency but also paving the way for personalized medicine and predictive analytics.

The following sections provide a comprehensive overview of the key shifts, segmentation insights, regional dynamics, and corporate strategies that drive this intersection of AI and biomedical applications. Each segment has been carefully examined to present a holistic view of a rapidly changing industry, one that harnesses the power of digital transformation to foster breakthroughs in clinical practice and research.

Transformative Shifts in the Landscape: Redefining Biomedical AI

In recent years, the biomedical industry has witnessed transformative shifts that have redefined both research and therapeutic approaches. Advanced algorithmic models and an influx of computational power have enabled faster, more accurate predictions in diagnostics and drug development. This transformation is driven by a profound integration between technology platforms and healthcare methodologies, where digital tools now standardize tasks once considered exclusive to human expertise.

A major driver in this shift has been the maturation of machine learning techniques which, when combined with large datasets, have significantly reduced the time required for clinical decision-making processes. Enhanced data visualization and advanced analytics empower stakeholders to identify subtle trends that were previously undetectable. These developments facilitate a transition from reactive care to proactive intervention strategies, ultimately driving better patient outcomes.

Moreover, this new era of biomedical innovation is supported by the integration of cloud computing, edge devices, and interconnected systems that allow for secure data sharing and a more holistic approach to patient monitoring. As technologies like natural language processing and robotic process automation mature, they offer scalable solutions that transform everyday operations into intelligent, self-optimizing ecosystems. This leap forward is not simply a matter of incremental improvement but a comprehensive rethinking of how biomedical research is executed and how healthcare is delivered.

Key Segmentation Insights: A Deep Dive into Market Dimensions

The segmentation insights provide an extensive framework that helps in understanding the diverse facets of the biomedical AI market. The analysis based on component highlights the division into hardware, services, and software, with hardware further dissected into memory, network devices, and processors. The services component is analyzed with a focus on consulting, implementation, integration, and maintenance, while the software category is examined across applications, middleware, and platforms. These layers underscore the multifaceted nature of technological integration and operational support.

When exploring the market based on technology, the field is segmented into computer vision, machine learning, natural language processing, and robotic process automation. Computer vision itself is studied through functionalities like facial recognition, image recognition, and pattern recognition. Machine learning is further divided into deep learning, reinforcement learning, supervised learning, and unsupervised learning, ensuring that every analytic nuance is captured. In parallel, natural language processing delves into chatbots, language translation, speech recognition, and text analysis, and robotic process automation is categorized by attended automation and unattended automation.

The segmentation based on business function reveals its own intricacies by focusing on customer service, finance, and operations. Customer service involves customer feedback analysis and personalized support, finance centers on fraud detection and risk management, and operations encapsulate process optimization and resource allocation. In addition to these dimensions, the application segmentation categorizes the market into clinical trials, diagnostics, patient monitoring, and therapeutics; with clinical trials covering data analysis and recruitment, diagnostics exploring pathology and radiology, patient monitoring looking at remote monitoring methods and wearable devices, and therapeutics emphasizing drug discovery and precision medicine.

Further analysis based on end user identifies segments such as academic and research institutes, government agencies, healthcare providers, and pharmaceutical companies. These segments are further refined into research centers and universities, public health organizations and regulatory bodies, clinics and hospitals, and biotech versus medtech companies respectively. Finally, the deployment mode segmentation distinguishes between cloud-based and on-premise setups, with cloud-based models diving into hybrid cloud, private cloud, and public cloud frameworks. The totality of these segmentation dimensions provides an intricate roadmap for stakeholders to precisely tailor their strategies in the biomedical AI market.

Based on Component, market is studied across Hardware, Services, and Software. The Hardware is further studied across Memory, Network Devices, and Processors. The Services is further studied across Consulting, Implementation, Integration, and Maintenance. The Software is further studied across Applications, Middleware, and Platforms.

Based on Technology, market is studied across Computer Vision, Machine Learning, Natural Language Processing, and Robotic Process Automation. The Computer Vision is further studied across Facial Recognition, Image Recognition, and Pattern Recognition. The Machine Learning is further studied across Deep Learning, Reinforcement Learning, Supervised Learning, and Unsupervised Learning. The Natural Language Processing is further studied across Chatbots, Language Translation, Speech Recognition, and Text Analysis. The Robotic Process Automation is further studied across Attended Automation and Unattended Automation.

Based on Business Function, market is studied across Customer Service, Finance, and Operations. The Customer Service is further studied across Customer Feedback Analysis and Personalized Support. The Finance is further studied across Fraud Detection and Risk Management. The Operations is further studied across Process Optimization and Resource Allocation.

Based on Application, market is studied across Clinical Trials, Diagnostics, Patient Monitoring, and Therapeutics. The Clinical Trials is further studied across Data Analysis and Recruitment. The Diagnostics is further studied across Pathology and Radiology. The Patient Monitoring is further studied across Remote Monitoring and Wearable Devices. The Therapeutics is further studied across Drug Discovery and Precision Medicine.

Based on End User, market is studied across Academic and Research Institutes, Government Agencies, Healthcare Providers, and Pharmaceutical Companies. The Academic and Research Institutes is further studied across Research Centers and Universities. The Government Agencies is further studied across Public Health Organizations and Regulatory Bodies. The Healthcare Providers is further studied across Clinics and Hospitals. The Pharmaceutical Companies is further studied across Biotech Companies and Medtech Companies.

Based on Deployment Mode, market is studied across Cloud-Based and On-Premise. The Cloud-Based is further studied across Hybrid Cloud, Private Cloud, and Public Cloud.

Key Regional Insights: Dynamics Across Global Markets

Examining regional trends reveals that market dynamics vary significantly across different parts of the world. In the Americas, robust innovation ecosystems and significant investment in health technology research are creating favorable conditions for rapid adoption of AI in biomedical applications. High levels of funding and a well-established digital infrastructure further reinforce this region's leading role.

Europe, Middle East & Africa is characterized by diverse regulatory environments that necessitate careful navigation. While Europe is often at the forefront of stringent regulatory standards and ethical guidelines, the Middle East and Africa are emerging as dynamic spaces where governmental initiatives and investments in public health are catalyzing the spread of smart technologies. This combination of tight governance and innovation-led public projects supports sustainable growth in biomedical AI strategies.

In the Asia-Pacific region, the emphasis is on scaling technologies to meet rising healthcare demands, underpinned by the rapid embrace of digital solutions. The region benefits from a large pool of tech-savvy professionals and cost-effective innovation, making it a hotbed for breakthrough applications in patient monitoring, diagnostics, and therapeutics. Each of these regions presents unique opportunities and challenges that industry players must address to fully leverage the transformative potential of AI in biomedicine.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights: Leaders Pioneering Biomedical AI

A detailed review of key companies in the biomedical AI market provides a vivid picture of the competitive landscape. Leading organizations such as AiCure, LLC; Arterys Inc.; Aspen Technology Inc; Atomwise Inc; and Augmedix, Inc. are driving innovation by merging advanced technology with healthcare objectives. Firms like Behold.ai Technologies Limited, BenevolentAI SA, and BioSymetrics Inc. are forging ahead with state-of-the-art solutions in pattern and image recognition, as well as predictive analytics.

Other pioneering companies including BPGbio Inc., Butterfly Network, Inc., and Caption Health, Inc. by GE Healthcare have made significant contributions towards integrating AI with medical imaging and diagnostic protocols. Cloud Pharmaceuticals, Inc., CloudMedX Inc., and Corti ApS are at the forefront of leveraging cloud-based infrastructures and automated decision-making systems to streamline patient care and data management. Deep Genomics Incorporated, along with Cyclica Inc by Recursion Pharmaceuticals, Inc., further expands the narrative by pushing the boundaries of genomic research and molecular data analysis.

Notably, organizations such as Deargen Inc, Euretos BV, Exscientia plc, and Google, LLC by Alphabet, Inc. underscore the deep-rooted collaboration between tech giants and innovative startups. These synergistic partnerships illustrate how multi-disciplinary expertise is reshaping areas like drug discovery, diagnostic accuracy, and personalized medicine. Additional players like Insilico Medicine, Intel Corporation, International Business Machines Corporation, and InveniAI LLC illustrate the impressive array of corporate investment in the sector. Companies such as Isomorphic Labs, Novo Nordisk A/S, Sanofi SA, Turbine Ltd., Viseven Europe OU, and XtalPi Inc. round out this group of industry leaders consistently pushing the envelope on research and commercial innovations in the biomedical AI arena.

The report delves into recent significant developments in the Artificial Intelligence in Biomedical Market, highlighting leading vendors and their innovative profiles. These include AiCure, LLC, Arterys Inc., Aspen Technology Inc, Atomwise Inc, Augmedix, Inc., Behold.ai Technologies Limited, BenevolentAI SA, BioSymetrics Inc., BPGbio Inc., Butterfly Network, Inc., Caption Health, Inc. by GE Healthcare, Cloud Pharmaceuticals, Inc., CloudMedX Inc., Corti ApS, Cyclica Inc by Recursion Pharmaceuticals, Inc., Deargen Inc, Deep Genomics Incorporated, Euretos BV, Exscientia plc, Google, LLC by Alphabet, Inc., Insilico Medicine, Intel Corporation, International Business Machines Corporation, InveniAI LLC, Isomorphic Labs, Novo Nordisk A/S, Sanofi SA, Turbine Ltd., Viseven Europe OU, and XtalPi Inc.. Actionable Recommendations: Strategic Guidance for Industry Leaders

Leaders operating in the dynamic landscape of biomedical AI must adopt agile strategies and invest in forward-thinking technologies. First, it is essential to continuously update technical infrastructure while emphasizing robust cybersecurity measures to protect sensitive health data. Upgrading to systems that support hybrid cloud configurations can offer a balanced approach, delivering both the scalability of public cloud services and the security of private systems.

Second, fostering partnerships between healthcare providers and technology innovators is pivotal. Industry players should initiate cross-disciplinary collaborations that include academic institutions, government agencies, and leading tech companies. Such partnerships not only expedite the development of breakthrough solutions but also ensure that these innovations are grounded in rigorous scientific methodologies.

Third, companies should allocate dedicated resources towards talent development and retention. Continuous professional training in the areas of machine learning, data analytics, and biomedical research will equip teams with the skills required to keep pace with rapidly evolving technologies. Investment in employee education, along with strategic hires, will bolster the capacity for research and operational efficiency.

Furthermore, organizations must regularly analyze market segmentation trends, adjusting product portfolios to meet diverse customer needs. By deploying comprehensive analyses that consider components such as hardware, services, software, and specific technological applications, companies can pivot swiftly in response to emerging demands. In addition, strategic geographical expansion should be considered, with special attention paid to regions showing high growth potential and favorable regulatory environments. These consolidated recommendations can serve as a roadmap for long-term strategic planning and competitive positioning.

Conclusion: Embracing a Data-Driven Future in Biomedical AI

In summary, the penetration of artificial intelligence into the biomedical arena has profoundly reshaped the way research, diagnostics, and patient care are approached. The landscape is undergoing a significant evolution, driven by technological advancements and a growing emphasis on data-driven decision-making. Detailed market segmentation reinforces how multifaceted the industry is, outlining clear distinctions based on component, technology, business function, application, end user, and deployment mode. At the regional level, variations in economic, regulatory, and demographic conditions underline the need for tailored strategies.

Companies operating in this dynamic environment illustrate a strong commitment to innovation and collaboration. Their ability to continuously integrate advanced technologies with traditional biomedical processes is setting the stage for transformative advancements in precision medicine and patient care. As the market matures, stakeholders must remain proactive in adapting to change and leveraging opportunities presented by emerging technologies.

This evolving narrative of biomedical AI, underpinned by comprehensive market segmentation and supported by a global network of key players, points towards a future where health systems become smarter, more efficient, and highly personalized. The journey ahead is challenging but filled with potential, and now is the time to harness these innovations to drive meaningful progress in healthcare.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing need for improved diagnostic tools and patient outcomes advancing
      • 5.1.1.2. Rising demand for personalized medicine boosting AI implementation in biomedical practices
      • 5.1.1.3. Surge in healthcare data generation
    • 5.1.2. Restraints
      • 5.1.2.1. Limitations of current AI algorithms in accurately understanding complex biological systems
    • 5.1.3. Opportunities
      • 5.1.3.1. Applying natural language processing to enhance clinical decision-making and data analysis
      • 5.1.3.2. Enhancing research and development through AI-driven computational models and simulations
    • 5.1.4. Challenges
      • 5.1.4.1. Managing data bias and accuracy concerns in AI applications within biomedicine
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology : Transformative impact of AI technologies on biomedical innovations and commercial strategies
    • 5.2.2. Application : Proliferation of AI applications in both pathology and radiology owing to their diagnostic accuracy and speed
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Artificial Intelligence in Biomedical Market, by Component

  • 6.1. Introduction
  • 6.2. Hardware
    • 6.2.1. Memory
    • 6.2.2. Network Devices
    • 6.2.3. Processors
  • 6.3. Services
    • 6.3.1. Consulting
    • 6.3.2. Implementation
    • 6.3.3. Integration
    • 6.3.4. Maintenance
  • 6.4. Software
    • 6.4.1. Applications
    • 6.4.2. Middleware
    • 6.4.3. Platforms

7. Artificial Intelligence in Biomedical Market, by Technology

  • 7.1. Introduction
  • 7.2. Computer Vision
    • 7.2.1. Facial Recognition
    • 7.2.2. Image Recognition
    • 7.2.3. Pattern Recognition
  • 7.3. Machine Learning
    • 7.3.1. Deep Learning
    • 7.3.2. Reinforcement Learning
    • 7.3.3. Supervised Learning
    • 7.3.4. Unsupervised Learning
  • 7.4. Natural Language Processing
    • 7.4.1. Chatbots
    • 7.4.2. Language Translation
    • 7.4.3. Speech Recognition
    • 7.4.4. Text Analysis
  • 7.5. Robotic Process Automation
    • 7.5.1. Attended Automation
    • 7.5.2. Unattended Automation

8. Artificial Intelligence in Biomedical Market, by Business Function

  • 8.1. Introduction
  • 8.2. Customer Service
    • 8.2.1. Customer Feedback Analysis
    • 8.2.2. Personalized Support
  • 8.3. Finance
    • 8.3.1. Fraud Detection
    • 8.3.2. Risk Management
  • 8.4. Operations
    • 8.4.1. Process Optimization
    • 8.4.2. Resource Allocation

9. Artificial Intelligence in Biomedical Market, by Application

  • 9.1. Introduction
  • 9.2. Clinical Trials
    • 9.2.1. Data Analysis
    • 9.2.2. Recruitment
  • 9.3. Diagnostics
    • 9.3.1. Pathology
    • 9.3.2. Radiology
  • 9.4. Patient Monitoring
    • 9.4.1. Remote Monitoring
    • 9.4.2. Wearable Devices
  • 9.5. Therapeutics
    • 9.5.1. Drug Discovery
    • 9.5.2. Precision Medicine

10. Artificial Intelligence in Biomedical Market, by End User

  • 10.1. Introduction
  • 10.2. Academic and Research Institutes
    • 10.2.1. Research Centers
    • 10.2.2. Universities
  • 10.3. Government Agencies
    • 10.3.1. Public Health Organizations
    • 10.3.2. Regulatory Bodies
  • 10.4. Healthcare Providers
    • 10.4.1. Clinics
    • 10.4.2. Hospitals
  • 10.5. Pharmaceutical Companies
    • 10.5.1. Biotech Companies
    • 10.5.2. Medtech Companies

11. Artificial Intelligence in Biomedical Market, by Deployment Mode

  • 11.1. Introduction
  • 11.2. Cloud-Based
    • 11.2.1. Hybrid Cloud
    • 11.2.2. Private Cloud
    • 11.2.3. Public Cloud
  • 11.3. On-Premise

12. Americas Artificial Intelligence in Biomedical Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Artificial Intelligence in Biomedical Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Artificial Intelligence in Biomedical Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Strategic agreement between Recursion and Exscientia to enhance AI-driven drug discovery process
    • 15.3.2. Insilico Medicine and NVIDIA launch nach0 transformer to enhance AI-driven biomedical discoveries
    • 15.3.3. HCA Healthcare's adoption of AI-powered Augmedix Go transforms emergency department documentation
    • 15.3.4. Bionl.AI Launches Innovative Platform for No-Code Biomedical Research
    • 15.3.5. Epistemic AI launches biomedical GPT at BIO
    • 15.3.6. NIH launches Bridge2AI program to expand the use of artificial intelligence in biomedical and behavioral research
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AiCure, LLC
  • 2. Arterys Inc.
  • 3. Aspen Technology Inc
  • 4. Atomwise Inc
  • 5. Augmedix, Inc.
  • 6. Behold.ai Technologies Limited
  • 7. BenevolentAI SA
  • 8. BioSymetrics Inc.
  • 9. BPGbio Inc.
  • 10. Butterfly Network, Inc.
  • 11. Caption Health, Inc. by GE Healthcare
  • 12. Cloud Pharmaceuticals, Inc.
  • 13. CloudMedX Inc.
  • 14. Corti ApS
  • 15. Cyclica Inc by Recursion Pharmaceuticals, Inc.
  • 16. Deargen Inc
  • 17. Deep Genomics Incorporated
  • 18. Euretos BV
  • 19. Exscientia plc
  • 20. Google, LLC by Alphabet, Inc.
  • 21. Insilico Medicine
  • 22. Intel Corporation
  • 23. International Business Machines Corporation
  • 24. InveniAI LLC
  • 25. Isomorphic Labs
  • 26. Novo Nordisk A/S
  • 27. Sanofi SA
  • 28. Turbine Ltd.
  • 29. Viseven Europe OU
  • 30. XtalPi Inc.

LIST OF FIGURES

  • FIGURE 1. ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET MULTI-CURRENCY
  • FIGURE 2. ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET MULTI-LANGUAGE
  • FIGURE 3. ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET RESEARCH PROCESS
  • FIGURE 4. ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENT, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY BUSINESS FUNCTION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY BUSINESS FUNCTION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DEPLOYMENT MODE, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DEPLOYMENT MODE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 23. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 29. ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET DYNAMICS
  • TABLE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HARDWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY MEMORY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY NETWORK DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PROCESSORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CONSULTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY IMPLEMENTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY INTEGRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY MAINTENANCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY MIDDLEWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPUTER VISION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY FACIAL RECOGNITION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY IMAGE RECOGNITION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PATTERN RECOGNITION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPUTER VISION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY MACHINE LEARNING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DEEP LEARNING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY REINFORCEMENT LEARNING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SUPERVISED LEARNING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY UNSUPERVISED LEARNING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY MACHINE LEARNING, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CHATBOTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY LANGUAGE TRANSLATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SPEECH RECOGNITION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TEXT ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ATTENDED AUTOMATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY UNATTENDED AUTOMATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY BUSINESS FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CUSTOMER SERVICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CUSTOMER FEEDBACK ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PERSONALIZED SUPPORT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CUSTOMER SERVICE, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY FINANCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY FRAUD DETECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY RISK MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY FINANCE, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY OPERATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PROCESS OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY RESOURCE ALLOCATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY OPERATIONS, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY RECRUITMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 64. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 65. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PATHOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 66. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY RADIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 67. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 68. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PATIENT MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 69. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY REMOTE MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 70. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY WEARABLE DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 71. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PATIENT MONITORING, 2018-2030 (USD MILLION)
  • TABLE 72. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 73. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 74. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PRECISION MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 75. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 76. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 78. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 79. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 80. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 81. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY GOVERNMENT AGENCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 82. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PUBLIC HEALTH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 83. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY REGULATORY BODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 84. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2030 (USD MILLION)
  • TABLE 85. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 86. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 87. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 88. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 89. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 90. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 91. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY MEDTECH COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 92. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 93. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 94. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLOUD-BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 95. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HYBRID CLOUD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 96. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PRIVATE CLOUD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 97. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PUBLIC CLOUD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 98. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLOUD-BASED, 2018-2030 (USD MILLION)
  • TABLE 99. GLOBAL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ON-PREMISE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 100. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 101. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 102. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 103. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 104. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPUTER VISION, 2018-2030 (USD MILLION)
  • TABLE 106. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY MACHINE LEARNING, 2018-2030 (USD MILLION)
  • TABLE 107. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 108. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, 2018-2030 (USD MILLION)
  • TABLE 109. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY BUSINESS FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 110. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CUSTOMER SERVICE, 2018-2030 (USD MILLION)
  • TABLE 111. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY FINANCE, 2018-2030 (USD MILLION)
  • TABLE 112. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY OPERATIONS, 2018-2030 (USD MILLION)
  • TABLE 113. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 115. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 116. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PATIENT MONITORING, 2018-2030 (USD MILLION)
  • TABLE 117. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 118. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 120. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2030 (USD MILLION)
  • TABLE 121. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 122. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 123. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 124. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLOUD-BASED, 2018-2030 (USD MILLION)
  • TABLE 125. AMERICAS ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 126. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 127. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 128. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 129. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 130. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 131. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPUTER VISION, 2018-2030 (USD MILLION)
  • TABLE 132. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY MACHINE LEARNING, 2018-2030 (USD MILLION)
  • TABLE 133. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 134. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, 2018-2030 (USD MILLION)
  • TABLE 135. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY BUSINESS FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 136. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CUSTOMER SERVICE, 2018-2030 (USD MILLION)
  • TABLE 137. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY FINANCE, 2018-2030 (USD MILLION)
  • TABLE 138. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY OPERATIONS, 2018-2030 (USD MILLION)
  • TABLE 139. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 141. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 142. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PATIENT MONITORING, 2018-2030 (USD MILLION)
  • TABLE 143. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 144. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 146. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2030 (USD MILLION)
  • TABLE 147. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 148. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 149. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 150. ARGENTINA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLOUD-BASED, 2018-2030 (USD MILLION)
  • TABLE 151. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 152. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 153. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 154. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 155. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPUTER VISION, 2018-2030 (USD MILLION)
  • TABLE 157. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY MACHINE LEARNING, 2018-2030 (USD MILLION)
  • TABLE 158. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 159. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, 2018-2030 (USD MILLION)
  • TABLE 160. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY BUSINESS FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 161. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CUSTOMER SERVICE, 2018-2030 (USD MILLION)
  • TABLE 162. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY FINANCE, 2018-2030 (USD MILLION)
  • TABLE 163. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY OPERATIONS, 2018-2030 (USD MILLION)
  • TABLE 164. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 166. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 167. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PATIENT MONITORING, 2018-2030 (USD MILLION)
  • TABLE 168. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 169. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 171. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2030 (USD MILLION)
  • TABLE 172. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 173. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 174. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 175. BRAZIL ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLOUD-BASED, 2018-2030 (USD MILLION)
  • TABLE 176. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 177. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 178. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 179. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 180. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 181. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPUTER VISION, 2018-2030 (USD MILLION)
  • TABLE 182. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY MACHINE LEARNING, 2018-2030 (USD MILLION)
  • TABLE 183. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 184. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, 2018-2030 (USD MILLION)
  • TABLE 185. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY BUSINESS FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 186. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CUSTOMER SERVICE, 2018-2030 (USD MILLION)
  • TABLE 187. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY FINANCE, 2018-2030 (USD MILLION)
  • TABLE 188. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY OPERATIONS, 2018-2030 (USD MILLION)
  • TABLE 189. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 191. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 192. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PATIENT MONITORING, 2018-2030 (USD MILLION)
  • TABLE 193. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 194. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 195. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 196. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2030 (USD MILLION)
  • TABLE 197. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 198. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 199. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 200. CANADA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLOUD-BASED, 2018-2030 (USD MILLION)
  • TABLE 201. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 202. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 203. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 204. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 205. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 206. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPUTER VISION, 2018-2030 (USD MILLION)
  • TABLE 207. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY MACHINE LEARNING, 2018-2030 (USD MILLION)
  • TABLE 208. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 209. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, 2018-2030 (USD MILLION)
  • TABLE 210. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY BUSINESS FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 211. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CUSTOMER SERVICE, 2018-2030 (USD MILLION)
  • TABLE 212. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY FINANCE, 2018-2030 (USD MILLION)
  • TABLE 213. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY OPERATIONS, 2018-2030 (USD MILLION)
  • TABLE 214. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 215. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 216. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 217. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PATIENT MONITORING, 2018-2030 (USD MILLION)
  • TABLE 218. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 219. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 220. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 221. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2030 (USD MILLION)
  • TABLE 222. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 223. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 224. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 225. MEXICO ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLOUD-BASED, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPUTER VISION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY MACHINE LEARNING, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY BUSINESS FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CUSTOMER SERVICE, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY FINANCE, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY OPERATIONS, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 241. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 242. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PATIENT MONITORING, 2018-2030 (USD MILLION)
  • TABLE 243. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 244. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 245. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 246. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2030 (USD MILLION)
  • TABLE 247. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 248. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 249. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 250. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLOUD-BASED, 2018-2030 (USD MILLION)
  • TABLE 251. UNITED STATES ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPUTER VISION, 2018-2030 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY MACHINE LEARNING, 2018-2030 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, 2018-2030 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY BUSINESS FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CUSTOMER SERVICE, 2018-2030 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY FINANCE, 2018-2030 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY OPERATIONS, 2018-2030 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PATIENT MONITORING, 2018-2030 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2030 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY CLOUD-BASED, 2018-2030 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 278. AUSTRALIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 279. AUSTRALIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 280. AUSTRALIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 281. AUSTRALIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 282. AUSTRALIA ARTIFICIAL INTELLIGENCE IN BIOMEDICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 283. AUSTRA